The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Neha Manpuria - JP Morgan Chase & Co, Research Division - Analyst
: My first question is on the India business. I know that the Wockhardt deal is still pending, but what's the thought process post the completion of
that acquisition? What are the key areas that we want to focus on in that business?
without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its
affiliated companies.
MAY 20, 2020 / 11:45AM, DRREDDY.NSE - Q4 2020 Dr.Reddy's Laboratories Ltd Earnings Call
Saumen Chakraborty - Dr. Reddy's Laboratories Limited - President, CFO, Global Head of IT & Business Process Excellence and Member of the
Mgmt Council
So right now, we are looking for the closure because a definitive agreement was signed, but the closure is contingent to completion of all the
conditions precedent. And along with the closure, we'll have the full integration plan, and then we can give a full response to your question. Right
now, it is too premature.
Question: Neha Manpuria - JP Morgan Chase & Co, Research Division - Analyst
: Okay. Sure. My second question is on generic Vascepa. Post litigation win at the district court, just wanted to get a sense on where we are in terms
of the product with the FDA?
Question: Neha Manpuria - JP Morgan Chase & Co, Research Division - Analyst
: But do we have a target action date on this? Or is there a CRL on this from an FDA perspective?
Question: Vishal Biraia - Aviva Life Insurance Company India Ltd. - Analyst
: The higher growth in Europe that we saw in this quarter was mainly led by some large tenders? Or I mean any other important aspects that you
would like to point out here?
Question: Vishal Biraia - Aviva Life Insurance Company India Ltd. - Analyst
: Okay. And what would be your guidance for the whole year of '21 in terms of growth in Europe that you see, some qualitative view?
Question: Vishal Biraia - Aviva Life Insurance Company India Ltd. - Analyst
: Okay. And Saumen, you mentioned that you expect an improvement in receivables gradually. So what will drive the improvement in receivables?
And actually what caused them to rise?
Saumen Chakraborty - Dr. Reddy's Laboratories Limited - President, CFO, Global Head of IT & Business Process Excellence and Member of the
Mgmt Council
Could you please repeat your question?
Question: Vishal Biraia - Aviva Life Insurance Company India Ltd. - Analyst
: This increase was primarily in India or...
Saumen Chakraborty - Dr. Reddy's Laboratories Limited - President, CFO, Global Head of IT & Business Process Excellence and Member of the
Mgmt Council
Overall, it is both in India as well as some other markets. But overall, our cash cycle remains in line with what it was in the previous year.
| 
